Loading...
The (Neutrophils + Monocyte)/Lymphocyte Ratio Is an Independent Prognostic Factor for Progression-Free Survival in Newly Diagnosed Multiple Myeloma Patients Treated With BCD Regimen
OBJECTIVE: Bortezomib is one of the important drugs that have made breakthrough progress in multiple myeloma (MM) in the past 10 years. However, the heterogeneity of its efficacy makes it difficult to predict the risk of disease progression. The purpose of this study is to determine the prognostic s...
Na minha lista:
| Udgivet i: | Front Oncol |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7492571/ https://ncbi.nlm.nih.gov/pubmed/32984029 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.01617 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|